Latest Case Studies
Latest Case Studies
Now available: the 2026 Biologics Contract Manufacturing Report
Discover the latest biologics CDMO market insights on manufacturing, investment, and M&A trends shaping the industry. Access the 2026 report today.Rare Disease Expert Insights
From Patients to Payers: Rethinking Value Communication in Rare Diseases
Companies face unique hurdles when communicating the value of rare disease treatments to payers. In this context, patient experience data can translate into insights on quality-of-life improvements, treatment burden, and caregiver impact, which helps contextualize clinical evidence and makes treatment value more tangible for payers. In this interview, our experts share best practices for designing payer communications with patient-informed value at the centre.
Preparing Rare Disease Manufacturers for JCA: The Role of Early Stakeholder Engagement
Since January 2025, new oncology medicines and advanced therapy medicinal products have been subject to the EU’s Joint Clinical Assessment. For rare disease medicine manufacturers, this is the most significant structural change to European market access in a generation. This article examines how stakeholder engagement helps rare disease manufacturers prepare for JCA and how to apply stakeholder management best practices in the JCA context.Creating Patient-Centric Clinical Trials in Rare Disease
The patient perspective should inform every aspect of trial design and planning, including study design and clinical protocol writing, patient-facing documents, the potential use of digital solutions, home visits and telemedicine, and home delivery of medications. This guide explores specific opportunities for sponsors, CROs, and trial sites to develop patient-centric clinical trials for rare diseases.
Serving Life Science Clients Globally
Improving the Life of Every Patient
We firmly believe that patient voices must be heard. By bridging our clients and patient advocacy groups, we empower patients to help the healthcare industry deliver what they value most in their care. We facilitate true and fruitful interactions that serve stakeholders across the ecosystem and benefit all patients.
~ Annabel de Maria
Chief Patient Officer
Let us tell you more about how our solutions bridge clinical research with routine medical care to